Tus kws kho mob
2022 May Bulletins
Hnub Tim pib siv tau lub khoos kas: Lub Tsib Hlis Ntuj Tim 02, 2022
Tshawb Nrhiav
Nthuav pom cov txiaj ntsig tshwm sim 1771 - 1780 ntawm 3685
Tus kws kho mob
Vascepa® (icosapent ethyl) - Commercial
Prior Authorization, Quantity Limit
Hnub Tim pib siv tau lub khoos kas: Lub Cuaj Hlis Ntuj Tim 01, 2024
Tus kws kho mob
P35-22 Medical Policy Updates: Coupe Health and Self-Funded Benefit Plans managed by Blue Cross and Blue Shield of Alabama
Hnub Tim pib siv tau ntawm lub khoos kas: Rau Hlis Ntuj Tim 01, 2022
Tus kws kho mob
Opioids Immediate Release (IR) and Extended Release (ER) New To Therapy with Daily Quantity Limit - Medicaid
Quantity Limit
Hnub Tim pib siv tau ntawm lub khoos kas: Rau Hlis Ntuj Tim 01, 2025
Tus kws kho mob
QP36-22 Commercial Pharmacy Benefit Exclusion for Xolair®
Hnub Tim pib siv tau lub khoos kas: Lub Tsib Hlis Ntuj Tim 11, 2022
Tus kws kho mob
QP37-22 MHCP Pharmacy Benefit Update – New Drug-Related Prior Authorization (PA) with Quantity Limit (QL) Criteria: VoxzogoTM (vosoritide)
Hnub Tim pib siv tau lub khoos kas: Lub Tsib Hlis Ntuj Tim 11, 2022
Tus kws kho mob
QP38-22 Updates to Authorization Request with Unlisted or Unspecified Codes
Hnub Tim pib siv tau lub khoos kas: Lub Tsib Hlis Ntuj Tim 11, 2022
Tus kws kho mob
P32-22 Medical Policy Updates: Coupe Health and Self-Funded Benefit Plans managed by Blue Cross and Blue Shield of Alabama
Hnub Tim pib siv tau lub khoos kas: Lub Tsib Hlis Ntuj Tim 02, 2022
Tus kws kho mob
P33-22 New Medical, Medical Drug and Behavioral Health Policy Management Updates—Effective July 4, 2022
Hnub Tim pib siv tau lub khoos kas: Lub Tsib Hlis Ntuj Tim 02, 2022
Tus kws kho mob
P30-22 eviCore Healthcare Specialty Utilization Management (UM) Program – Medical Oncology Drug Prior Authorization Updates
Hnub Tim pib siv tau lub khoos kas: Lub Tsib Hlis Ntuj Tim 02, 2022